dipyridamole has been researched along with Innate Inflammatory Response in 15 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1." | 9.34 | A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. ( Abebe, KZ; Borowski, L; Comer, D; Cyktor, J; Gillespie, DG; Jackson, EK; Klamar-Blain, C; Macatangay, BJC; Mellors, JW; Riddler, SA; Rinaldo, CR, 2020) |
| "Seven-day oral treatment with dipyridamole increases the circulating adenosine concentration and augments the antiinflammatory response during experimental human endotoxemia, which is associated with a faster decline in proinflammatory cytokines." | 9.15 | Dipyridamole augments the antiinflammatory response during human endotoxemia. ( Heemskerk, S; Peters, WH; Pickkers, P; Ramakers, BP; Riksen, NP; Smits, P; Stal, TH; van den Broek, P; van der Hoeven, JG, 2011) |
| "Dipyridamole prevented the progression of DN by elevating endogenous levels of protecting adenosine, leading to reduction in inflammation and intrinsic apoptosis." | 7.81 | Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. ( Abd El Galil, KH; Al-Gayyar, MM; Elsherbiny, NM, 2015) |
| "These results suggest that dipyridamole may ameliorate brain endothelial injury after inflammation and/or metabolic insults." | 7.76 | Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. ( Guo, S; Lo, EH; Ning, M; Stins, M, 2010) |
| " We have found that the beneficial effects of dipyridamole therapy are due to its ability to increase tissue nitric oxide bioavailability that corrects tissue redox imbalance." | 6.46 | Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. ( Fang, K; Kevil, CG; Pattillo, CB; Terracciano, J, 2010) |
| " We hypothesized that dipyridamole, which inhibits cellular adenosine uptake, could raise the extracellular adenosine concentration and dampen chronic inflammation associated with human immunodeficiency virus (HIV) type 1." | 5.34 | A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation. ( Abebe, KZ; Borowski, L; Comer, D; Cyktor, J; Gillespie, DG; Jackson, EK; Klamar-Blain, C; Macatangay, BJC; Mellors, JW; Riddler, SA; Rinaldo, CR, 2020) |
| "Seven-day oral treatment with dipyridamole increases the circulating adenosine concentration and augments the antiinflammatory response during experimental human endotoxemia, which is associated with a faster decline in proinflammatory cytokines." | 5.15 | Dipyridamole augments the antiinflammatory response during human endotoxemia. ( Heemskerk, S; Peters, WH; Pickkers, P; Ramakers, BP; Riksen, NP; Smits, P; Stal, TH; van den Broek, P; van der Hoeven, JG, 2011) |
| "Dipyridamole prevented the progression of DN by elevating endogenous levels of protecting adenosine, leading to reduction in inflammation and intrinsic apoptosis." | 3.81 | Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis. ( Abd El Galil, KH; Al-Gayyar, MM; Elsherbiny, NM, 2015) |
| "These results suggest that dipyridamole may ameliorate brain endothelial injury after inflammation and/or metabolic insults." | 3.76 | Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. ( Guo, S; Lo, EH; Ning, M; Stins, M, 2010) |
| " We have found that the beneficial effects of dipyridamole therapy are due to its ability to increase tissue nitric oxide bioavailability that corrects tissue redox imbalance." | 2.46 | Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses. ( Fang, K; Kevil, CG; Pattillo, CB; Terracciano, J, 2010) |
| " The immune-specific amplification of prednisolone anti-inflammatory activity by dipyridamole did not extend to glucocorticoid-mediated adverse effects, including corticosterone suppression or increased expression of tyrosine aminotransferase, in vivo after repeat dosing in rats." | 1.35 | Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. ( Avery, W; Borisy, AA; Farwell, M; Finelli, AL; Fraser, CC; Zimmermann, GR, 2009) |
| "Pre-treatment with choline salicylate and colchicine reduced swelling while pre-treatment with dipyridamole increased edema following cryoglobulin inoculation." | 1.27 | Cryoglobulin-induced inflammation. ( Denko, CW, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Huang, B | 1 |
| Chen, Z | 1 |
| Geng, L | 1 |
| Wang, J | 1 |
| Liang, H | 1 |
| Cao, Y | 1 |
| Chen, H | 1 |
| Huang, W | 1 |
| Su, M | 1 |
| Wang, H | 2 |
| Xu, Y | 1 |
| Liu, Y | 1 |
| Lu, B | 1 |
| Xian, H | 1 |
| Li, H | 2 |
| Ren, L | 1 |
| Xie, J | 1 |
| Ye, L | 1 |
| Zhao, J | 1 |
| Chen, P | 1 |
| Zhang, L | 1 |
| Zhao, S | 1 |
| Zhang, T | 1 |
| Xu, B | 1 |
| Che, D | 1 |
| Si, W | 1 |
| Gu, X | 1 |
| Zeng, L | 1 |
| Wang, Y | 1 |
| Li, D | 1 |
| Zhan, Y | 1 |
| Delfouneso, D | 1 |
| Lew, AM | 1 |
| Cui, J | 1 |
| Tang, WH | 1 |
| Zhang, Y | 2 |
| Gong, S | 1 |
| Bai, F | 1 |
| Yang, M | 1 |
| Utay, NS | 1 |
| Overton, ET | 1 |
| Macatangay, BJC | 1 |
| Jackson, EK | 1 |
| Abebe, KZ | 1 |
| Comer, D | 1 |
| Cyktor, J | 1 |
| Klamar-Blain, C | 1 |
| Borowski, L | 1 |
| Gillespie, DG | 1 |
| Mellors, JW | 1 |
| Rinaldo, CR | 1 |
| Riddler, SA | 1 |
| Elsherbiny, NM | 1 |
| Al-Gayyar, MM | 1 |
| Abd El Galil, KH | 1 |
| Zimmermann, GR | 1 |
| Avery, W | 1 |
| Finelli, AL | 1 |
| Farwell, M | 1 |
| Fraser, CC | 1 |
| Borisy, AA | 1 |
| Guo, S | 1 |
| Stins, M | 1 |
| Ning, M | 1 |
| Lo, EH | 1 |
| Pattillo, CB | 1 |
| Fang, K | 1 |
| Terracciano, J | 1 |
| Kevil, CG | 1 |
| Ramakers, BP | 1 |
| Riksen, NP | 1 |
| Stal, TH | 1 |
| Heemskerk, S | 1 |
| van den Broek, P | 1 |
| Peters, WH | 1 |
| van der Hoeven, JG | 1 |
| Smits, P | 1 |
| Pickkers, P | 1 |
| Sampaio, FP | 1 |
| Castro, PR | 1 |
| Marques, SM | 1 |
| Campos, PP | 1 |
| Ferreira, MA | 1 |
| Andrade, SP | 1 |
| Dong, H | 1 |
| Osmanova, V | 1 |
| Epstein, PM | 1 |
| Brocke, S | 1 |
| Paris, D | 1 |
| Town, T | 1 |
| Parker, T | 1 |
| Humphrey, J | 1 |
| Mullan, M | 1 |
| Brozna, JP | 1 |
| Horan, M | 1 |
| Carson, SD | 1 |
| Denko, CW | 1 |
| Harker, LA | 1 |
| Slichter, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection[NCT04410328] | Phase 3 | 99 participants (Actual) | Interventional | 2020-10-21 | Completed | ||
| The Effects of Oral Dipyridamole Treatment on the Innate Immune Response During Human Endotoxemia.[NCT01091571] | Phase 4 | 30 participants (Anticipated) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for dipyridamole and Innate Inflammatory Response
| Article | Year |
|---|---|
Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses.
Topics: Animals; Dipyridamole; Down-Regulation; Humans; Immunity, Innate; Inflammation; Ischemia; Neovascula | 2010 |
2 trials available for dipyridamole and Innate Inflammatory Response
| Article | Year |
|---|---|
A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.
Topics: Adolescent; Adult; Biomarkers; Chronic Disease; Dipyridamole; Double-Blind Method; HIV Infections; H | 2020 |
Dipyridamole augments the antiinflammatory response during human endotoxemia.
Topics: Acetylcholine; Creatinine; Dipyridamole; Double-Blind Method; Endotoxemia; Endotoxins; Equilibrative | 2011 |
12 other studies available for dipyridamole and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Mucosal Profiling of Pediatric-Onset Colitis and IBD Reveals Common Pathogenics and Therapeutic Pathways.
Topics: Antigens, CD; Apyrase; B-Lymphocytes; Cell Death; Cellular Microenvironment; Child; Cohort Studies; | 2019 |
Immune Activation and Inflammation in People With Human Immunodeficiency Virus: Challenging Targets.
Topics: Animals; Dipyridamole; HIV; HIV Infections; Humans; Inflammation; Simian Acquired Immunodeficiency S | 2020 |
Nephroprotective role of dipyridamole in diabetic nephropathy: Effect on inflammation and apoptosis.
Topics: Adenosine; Animals; Apoptosis; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Nephropath | 2015 |
Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug.
Topics: Animals; Anti-Inflammatory Agents; Dipyridamole; Drug Therapy, Combination; Glucocorticoids; Humans; | 2009 |
Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells.
Topics: Brain; Cell Hypoxia; Cell Line; Cell Survival; Cytotoxins; Dipyridamole; Endothelium, Vascular; Huma | 2010 |
Genetic background determines inflammatory angiogenesis response to dipyridamole in mice.
Topics: Acetylglucosaminidase; Animals; Blood Flow Velocity; Collagen; Dipyridamole; Hemoglobins; Inflammati | 2012 |
Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes.
Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Chemotaxis; Colforsin; Co | 2006 |
beta-Amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents.
Topics: Amyloid beta-Peptides; Animals; Aorta; Cyclic GMP; Dipyridamole; Endothelin-1; In Vitro Techniques; | 2000 |
Dipyridamole inhibits O2- release and expression of tissue factor activity by peripheral blood monocytes stimulated with lipopolysaccharide.
Topics: Biological Transport; Cells, Cultured; Depression, Chemical; Dipyridamole; Endotoxins; Fibrinolytic | 1990 |
Cryoglobulin-induced inflammation.
Topics: Alprostadil; Animals; Choline; Colchicine; Cryoglobulins; Crystallization; Dipyridamole; Drug Combin | 1985 |
Platelet and fibrinogen consumption in man.
Topics: Blood Cell Count; Blood Platelets; Catheterization; Cell Survival; Dipyridamole; Disseminated Intrav | 1972 |